A single-compound vial is the easiest to verify against its certificate, while blends are harder to test
Specifically, we are finalizing a modification to the text of paragraph (l)(3)(iii) to remove the term equal such that the finalized regulation text at 425.610(l)(3)(iii) will read as follows, The performance payment limit or loss recoupment limit is set to the lesser of the amount calculated under paragraph (l)(2)(ii) of this section or the alternative amount calculated under paragraph (l)(3)(ii) of this section. (2) Exclude ACOs That Fall Below 5,000 Assigned Beneficiaries in any BY From Policies Providing Certain Low Revenue ACOs Participating in the BASIC Track Increased Opportunities To Share in Savings (a) Background With the CY 2023 PFS final rule (87 FR 69946 through 69952), we finalized an approach, under our authority of section 1899(i)(3) of the Act, [411] to expand the eligibility criteria to qualify for shared savings payments to enable certain low revenue ACOs participating in the BASIC track to share in savings even if the ACO does not meet the MSR as required under section 1899(d)(1)(B)(i) of the Act
Evidence level: Misleading framing Sources: ClinicalTrials.gov exact-name search, accessed 2026-07-12 How to read this: The absence of human trials means human adverse effects are largely unknown
doi:10.3390/ph17040461 McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM
